OBJECTIVE： To observe the clinical efficacy and safety of Bailing capsules in adjunctive treatment of children of henoch-schonlein purpura nephritis. METHODS： 97 non-nephrotic syndrome type of HSPN children with admitted in our hospital were divided into observation group （48 cases） and routine group （49 cases） according to admission order. Routine group was given benazepril 2.5-5 mg， qd， and the children with hematuresis compliacting with albuminuria and acute nephritis additionally received mycophenolate mofetil 15-20 mg/kg， bid or prednisone 0.5-1 mg/（kg·d）. Observation group was additionally given Bailing capsule 0.5-1.0 g，tid， on the basis of routine group. Both groups received treatment for more than 4 weeks. Clinical efficacy of 2 groups were observed after treatment as well as the levels of serum inflammatory factors （IL-6， IL-10， IL-18， TNF-α）， peripheral blood cell immune level （CD3+， CD4+， CD8+， CD4+/CD8+）， body fluid immune level （IgM， IgA， IgG） before and after treatment. The occurrence of ADR was compared. RESULTS： The markedly effective rate of observation group was 75.00％， which was significantly higher than 55.10％ of routine group （P＜0.05）. There was no statistical significance in serum inflammatory factor， peripheral blood cell immune level and body fluid immune level （IgM，IgA，IgG） before treatment （P＞0.05）. After treatment， the levels of IL-6， IL-18， TNF-α， IgM， IgA and IgG of 2 groups were decreased significantly， while the levels of IL-10， CD3+ and CD4+/CD8+ were increased significantly； the observation group was significantly better than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： For adjunctive treatment of non-nephrotic syndrome type of HSPN， Bailing capsule can significantly improve clinical efficacy and immune level with good safety.